Cyprium's CUTX-101 Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Menkes Disease
Shots:
- The US FDA has granted BTD to CUTX-101 for the potential treatment of Menkes disease
- The FDA has previously ODD- FTD and RPDD to CUTX-101 for the treatment of Menkes disease. Additionally- the EMA has previously granted ODD to CUTX-101
- The rolling submission of NDA to the US FDA for CUTX-101 is expected to be initiated in Q1’21 and to be completed by the end of the Q2’21
Ref: GlobeNewswire | Image: Cyprium
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
